Insiders who reported open-market trades in the last 12 months at the companies MPM BIOVENTURES 2018, L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Kush Parmar - $3.65M in TRDA purchases and sales in the last 12 months
MPM BIOVENTURES 2018, L.P. is an investment firm, tracked as 10% Owner of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 6 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has MPM BIOVENTURES 2018, L.P. submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has MPM BIOVENTURES 2018, L.P. been buying or selling stock?
Recorded transactions: 1 open-market purchase ($20.03M) and 14 open-market sales ($4.52M) across all tracked filings.
MPM BIOVENTURES 2018, L.P. is 10% Owner of Entrada Therapeutics, Inc. (TRDA). 6 SEC Form 4 filings on record going back to 2024, most recently on 9 September 2026. Most recent open-market trade: sold $206K of TRDA on 9 September 2026. Lifetime open-market purchases: $20.03M. Lifetime open-market sales: $4.52M.
Recent transactions
18
The latest 18 SEC Form 4 transactions reported by MPM BIOVENTURES 2018, L.P..
InsiderAlpha's records for MPM BIOVENTURES 2018, L.P. go back to 2024: 6 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $20.03M (1 buy totaling $20.03M). The largest single buy on record is $20.03M of AKTS in 2026. Sales side: 14 recorded sales totaling $4.52M, so the filing history runs buy-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
